SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Isleworth Healthcare Acquisition Corp. (Nasdaq – ISLE)

BALA CYNWYD – April 27, 2022 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Isleworth Healthcare Acquisition Corp. (“Isleworth ” or the “Company”) (Nasdaq – ISLE) for possible breaches of fiduciary duty and other violations of federal and state law in connection with a merger agreement pursuant to which Isleworth , a special purpose acquisition company, will combine with Cytovia Holdings, Inc.(“Cytovia”), a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, and result in Cytovia becoming a publicly-listed company. Under the terms of the agreement, Isleworth shareholders will retain ownership of approximately 33% of the combined company.

The investigation concerns whether the Isleworth Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution of ownership interest in the combined company.

If you own shares of Isleworth stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 877-534-2590.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.